Wall Street Zen Upgrades GT Biopharma (NASDAQ:GTBP) to Hold

GT Biopharma (NASDAQ:GTBP) was upgraded by investment analysts at Wall Street Zen to a “hold” rating in a research note issued on Saturday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of GT Biopharma in a research report on Friday, April 10th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of “Sell”.

GT Biopharma Price Performance

GTBP opened at $0.51 on Friday. GT Biopharma has a fifty-two week low of $0.26 and a fifty-two week high of $3.85. The firm has a market capitalization of $18.53 million, a P/E ratio of -0.08 and a beta of 0.86. The company’s 50-day moving average is $0.40 and its 200 day moving average is $0.52.

GT Biopharma (NASDAQ:GTBP) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.03). On average, equities research analysts expect that GT Biopharma will post -0.34 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in GT Biopharma stock. SeaCrest Wealth Management LLC bought a new stake in shares of GT Biopharma, Inc. (NASDAQ:GTBP) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 50,000 shares of the company’s stock, valued at approximately $37,000. SeaCrest Wealth Management LLC owned 0.47% of GT Biopharma as of its most recent SEC filing. 8.15% of the stock is owned by institutional investors.

GT Biopharma Company Profile

GT Biopharma, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events.

The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).